Novo Nordisk A/S vs SMX Security Matters plc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while SMX Security Matters plc trades at $3.79 (market cap $4.13M). The key difference: Novo Nordisk A/S is far larger — about 40026.6× SMX Security Matters plc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and SMX Security Matters plc for 21 Days on average.
| NVO | SMX | |
|---|---|---|
Market Cap | $165.31B | $4.13M |
Volume | 11,432,838 | 124,362 |
Sector | Health | Industrials |
52-Week High | $63.98 | $74.08K |
52-Week Low | $35.29 | $3.79 |
Typical Hold Time | 116 Days | 21 Days |
Enterprise Value | $179.56B | -$27.20M |
Dividend Yield | 4.71% | — |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
SMX trades at $3.79, down 2.82% today, amid a bearish technical signal from moving averages despite oversold RSI readings. The company reported no revenue for 2025, with a net loss of $169.18 million and negative cash flow from operations, though financing activities provided a net cash inflow. Recent news highlights SMX's focus on recycled plastic verification and digital material passports, gaining media attention from outlets like Forbes and the Boston Herald in late 2026.
The outlook is highly speculative given the absence of revenue and deep losses; investment hinges on successful commercialization of its technology. Key risks include execution challenges, cash burn, and competitive pressures in the recycling sector. Analyst sentiment is cautious due to the lack of profitability and substantial financial deficits.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →